MedTrace Logo

Apixaban Versus Warfarin in Patients With Left Ventricular Thrombus

NCT02982590 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2021-07-08

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to compare the novel oral anticoagulant apixaban with the standard therapy of warfarin on the size reduction or resolution of left ventricular thrombus over 3 months.

Conditions

  • Left Ventricular Thrombosis

Interventions

DRUG

Apixaban 5 MG Oral Tablet [ELIQUIS]

Apixaban is licensed for treatment of deep vein thrombosis and pulmonary embolism. Hence, a good study drug for left ventricular thrombosis for possibility of a new indication.

DRUG

Warfarin Sodium

as controlled arm since warfarin is the standard therapy for LV thrombus

Sponsors & Collaborators

  • Institut Jantung Negara

    collaborator OTHER

  • Universiti Sains Malaysia

    lead OTHER

Principal Investigators

  • Dr W. Yus Haniff W. Isa, M.MED · Universiti Sains Malaysia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-30
Primary Completion
2018-11-30
Completion
2018-11-30

Countries

  • Malaysia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02982590 on ClinicalTrials.gov